A previous study from 2021 showed that the chronic inflammation biomarker soluble urokinase Plasminogen Activator Receptor (suPAR) serves as a robust indicator for identifying patients with COVID-19 who will not develop respiratory failure and, therefore, may not require treatment with mechanical ventilation [15]. Here, PLAUR is linked to COVID-19.